P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
<p>Abstract</p> <p>Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic myeloid leukemia (CML) and confers significant benefit for most patients; however, a substantial number of patients are either initially refractory or develop resist...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-10-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/1/1/15 |